Lv4
706 积分 2022-06-06 加入
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
1天前
已完结
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer
24天前
已完结
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
26天前
已完结
Tumour-agnostic kinase inhibitors
26天前
已完结
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
26天前
已完结
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
26天前
已完结
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
1个月前
已完结
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
1个月前
已完结
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer
1个月前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
2个月前
已完结
皖公网安备34019202002308
